GRAMD1B Knockdown and Cholesterol Depletion
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Corresponding Organization : Memorial Sloan Kettering Cancer Center
Other organizations : Wellcome Sanger Institute, European Bioinformatics Institute, Tri-Institutional PhD Program in Chemical Biology, Cornell University, Newcastle University, University of Leeds
Variable analysis
- Cholesterol depletion media (DMEM, 10% lipoprotein-free FBS, 1% antibiotics, 10 μmol/L simvastatin, and 200 μmol/L mevalonic acid, 4 μg/mL dox)
- Dox-containing control media (DMEM, 10% FBS, 1% antibiotics, 4 μg/mL dox)
- Cholesterol levels (confirmed through Promega's cholesterol Glo assay)
- Invasion assays
- Cell line: SKMEL2 cells
- Initial cell seeding: 100,000 NT or GRAMD1B shRNA SKMEL2 cells
- Pretreatment: 48 hours in 4 μg/mL dox-containing media to induce GRAMD1B knockdown
- Dox concentration: 4 μg/mL in both control and cholesterol depletion media
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!